Australia markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
41.05-0.68 (-1.63%)
At close: 04:00PM EDT

Roche Holding AG

Konzern Hauptsitz
Grenzacherstrasse 124
Basel 4070
Switzerland
41 61 688 11 11
https://www.roche.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees100,920

Key executives

NameTitlePayExercisedYear born
Dr. Severin Schwan Ph.D.CEO & Exec. Director7.68MN/A1967
Dr. Alan HippeChief Financial & Information Officer4.4MN/A1967
Ms. Cristina A. WilburChief People Officer3.15MN/A1967
Dr. Johannes Carolus Clevers M.D., Ph.D.Head of Roche Pharma Research & Early Devel.357.67kN/A1957
Dr. Thomas SchineckerChief Exec. Officer of Roche Diagnostics3.02MN/A1975
Mr. William N. AndersonChief Exec. Officer of Roche Pharmaceuticals6.63MN/A1966
Dr. Bruno EschliHead of Investor RelationsN/AN/AN/A
Ms. Claudia BockstiegelGen. CounselN/AN/A1964
Ms. Pascale SchmidtChief Compliance OfficerN/AN/A1973
Ms. Barbara SchadlerHead of Group CommunicationsN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate governance

Roche Holding AG’s ISS governance QualityScore as of 1 October 2022 is 9. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.